350 related articles for article (PubMed ID: 35849317)
21. Efficacy and safety of the dual bronchodilator combination umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical trials.
Ray R; Tombs L; Naya I; Compton C; Lipson DA; Boucot I
Pulm Pharmacol Ther; 2019 Aug; 57():101802. PubMed ID: 31096036
[TBL] [Abstract][Full Text] [Related]
22. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
23. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
[TBL] [Abstract][Full Text] [Related]
24. Baseline Characteristics and ICS/LAMA/LABA Response in Asthma: Analyses From the CAPTAIN Study.
Boulet LP; Abbott C; Brusselle G; Edwards D; Oppenheimer J; Pavord ID; Pizzichini E; Sagara H; Slade D; Wechsler ME; Gibson PG
J Allergy Clin Immunol Pract; 2024 May; 12(5):1244-1253.e8. PubMed ID: 38309696
[TBL] [Abstract][Full Text] [Related]
25. Once-daily long-acting beta₂-agonists/inhaled corticosteroids combined inhalers versus inhaled long-acting muscarinic antagonists for people with chronic obstructive pulmonary disease.
Sliwka A; Jankowski M; Gross-Sondej I; Storman M; Nowobilski R; Bala MM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012355. PubMed ID: 30141826
[TBL] [Abstract][Full Text] [Related]
26. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
27. Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.
Kalberg C; O'Dell D; Galkin D; Newlands A; Fahy WA
Drugs R D; 2016 Jun; 16(2):217-27. PubMed ID: 27028749
[TBL] [Abstract][Full Text] [Related]
28. Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study.
Mannino D; Bogart M; Wu B; Germain G; Laliberté F; MacKnight SD; Jung Y; Stiegler M; Duh MS
Respir Med; 2022 Jun; 197():106807. PubMed ID: 35429764
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of New Users of Single- and Multiple-Inhaler Triple Therapy for COPD in Primary Care in England.
Rothnie KJ; Joksaite S; Sansbury LB; Compton C; Di Boscio V; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2022; 17():1455-1466. PubMed ID: 35769225
[TBL] [Abstract][Full Text] [Related]
30. Single-Inhaler Triple Therapy and Health-Related Quality of Life in COPD: The IMPACT Study.
Tabberer M; Jones CE; Kilbride S; Halpin DMG; Lomas DA; Pascoe S; Singh D; Wise RA; Criner GJ; Lange P; Dransfield MT; Han MK; Martinez FJ; Kaisermann MC; Lipson DA
Adv Ther; 2020 Sep; 37(9):3775-3790. PubMed ID: 32647911
[TBL] [Abstract][Full Text] [Related]
31. Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease.
Parri G; Nieri D; Roggi MA; Vagaggini B; Celi A; Paggiaro P
Expert Rev Respir Med; 2018 Dec; 12(12):997-1005. PubMed ID: 30463451
[No Abstract] [Full Text] [Related]
32. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
33. Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany.
Beeh KM; Rothnie KJ; Claussen J; Hardtstock F; Knapp RK; Wilke T; Czira A; Compton C; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2024; 19():945-956. PubMed ID: 38646606
[TBL] [Abstract][Full Text] [Related]
34. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
[TBL] [Abstract][Full Text] [Related]
35. Assessment of COPD-related outcomes in patients initiating a once daily or twice daily ICS/LABA.
Stanford RH; Parker ED; Reinsch TK; Buikema AR; Blauer-Peterson C
Respir Med; 2019 Apr; 150():1-7. PubMed ID: 30961933
[TBL] [Abstract][Full Text] [Related]
36. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA; Barnacle H; Birk R; Brealey N; Locantore N; Lomas DA; Ludwig-Sengpiel A; Mohindra R; Tabberer M; Zhu CQ; Pascoe SJ
Am J Respir Crit Care Med; 2017 Aug; 196(4):438-446. PubMed ID: 28375647
[TBL] [Abstract][Full Text] [Related]
37. Benefit of Prompt versus Delayed Use of Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Following a COPD Exacerbation.
Mannino D; Bogart M; Germain G; Huang SP; Ismaila AS; Laliberté F; Jung Y; MacKnight SD; Stiegler MA; Duh MS
Int J Chron Obstruct Pulmon Dis; 2022; 17():491-504. PubMed ID: 35281476
[TBL] [Abstract][Full Text] [Related]
38. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.
Feldman GJ; Sousa AR; Lipson DA; Tombs L; Barnes N; Riley JH; Patel S; Naya I; Compton C; Alcázar Navarrete B
Adv Ther; 2017 Nov; 34(11):2518-2533. PubMed ID: 29094315
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of fluticasone furoate/umeclidinium bromide/vilanterol and umeclidinium bromide/vilanterol in the management of moderate and severe COPD in China.
Zhou Y; Duan S; Zhang L; Peng F
Respir Med; 2024 May; 226():107632. PubMed ID: 38621548
[TBL] [Abstract][Full Text] [Related]
40. Impact of ICS/LABA and LABA/LAMA FDCs on functional and clinical outcomes in COPD: A network meta-analysis.
Calzetta L; Di Marco F; Blasi F; Cazzola M; Centanni S; Micheletto C; Rossi A; Rogliani P
Pulm Pharmacol Ther; 2019 Dec; 59():101855. PubMed ID: 31639476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]